383
Participants
Start Date
April 13, 2015
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
ASP0456
oral
Placebo
oral
Site: 35, Aichi
Site: 36, Aichi
Site: 27, Chiba
Site: 28, Chiba
Site: 29, Chiba
Site: 30, Chiba
Site: 48, Fukuoka
Site: 49, Fukuoka
Site: 50, Fukuoka
Site: 1, Hokkaido
Site: 2, Hokkaido
Site: 45, Hyōgo
Site: 46, Hyōgo
Site: 47, Hyōgo
Site: 22, Kanagawa
Site: 23, Kanagawa
Site: 24, Kanagawa
Site: 25, Kanagawa
Site: 26, Kanagawa
Site: 44, Kyoto
Site: 37, Osaka
Site: 38, Osaka
Site: 39, Osaka
Site: 40, Osaka
Site: 41, Osaka
Site: 42, Osaka
Site: 43, Osaka
Site: 31, Saitama
Site: 32, Saitama
Site: 33, Saitama
Site: 34, Saitama
Site: 10, Tokyo
Site: 11, Tokyo
Site: 12, Tokyo
Site: 13, Tokyo
Site: 14, Tokyo
Site: 15, Tokyo
Site: 16, Tokyo
Site: 17, Tokyo
Site: 18, Tokyo
Site: 19, Tokyo
Site: 20, Tokyo
Site: 21, Tokyo
Site: 3, Tokyo
Site: 4, Tokyo
Site: 5, Tokyo
Site: 6, Tokyo
Site: 7, Tokyo
Site: 8, Tokyo
Site: 9, Tokyo
Lead Sponsor
Astellas Pharma Inc
INDUSTRY